Drug Topics

AUGUST 15, 2024

New prices will go into effect on January 1, 2026, for individuals covered by Medicare Part D prescription drugs.

198

198

Pharmacy Times

AUGUST 15, 2024

The new prices are expected to go into effect for patients with Medicare Part D on January 1, 2026.

149

149

Fierce Healthcare

MARCH 15, 2023

CMS gives an early look at how it plans to negotiate Part D drug prices in 2026 dmuoio Wed, 03/15/2023 - 17:35

75

75

Fierce Pharma

OCTOBER 30, 2024

Ever since the FDA rejected zuranolone in major depressive disorder last year, brai | In the wake of a recent round of layoffs, the company this week revealed that it’s discontinuing a commercial medicine and giving up hopes for a pair of pipeline prospects.

FDA 117

FDA 117

Fierce Healthcare

OCTOBER 4, 2024

A proposed rule from the Centers for Medicare & Medicaid Services (CMS) released Oct. | CMS is looking to shake up the risk adjustment model and wants the ability to suspend shady brokers from the insurance marketplace, the agency wrote among other updates in a new proposed rule.

Insurance 105

Insurance 105

Fierce Pharma

SEPTEMBER 7, 2023

Now that the Centers for Medicare & Medicaid Services (CMS) has revealed its li | Now that the CMS has revealed its list of the first 10 drugs subject to Medicare price negotiations under the Inflation Reduction Act, it’s time to consider the financial implications for affected companies.

115

115

Pharmaceutical Technology

NOVEMBER 19, 2024

Regenxbio’s plans toward a BLA filing in 2026 after positive data from the Phase I/II AFINITY DUCHENNE trial.

52

52

Pharmacy Times

AUGUST 30, 2023

Any new prices established after negotiations will be effective on January 1, 2026.

132

132

STAT

SEPTEMBER 6, 2023

29, Medicare released its highly anticipated list of 10 therapies for which it plans to establish a price by 2026.

134

134

Mission-Driven Marketing Blog

NOVEMBER 1, 2023

Communities of Excellence 2026 (COE) announces strategic partnerships with TAPP Network and PMG Consulting, to improve the quality of life for our nation.

52

52

Fierce Pharma

SEPTEMBER 28, 2023

Riding on the growth of long-acting antiretroviral therapy Cabenuva, GSK is laying out a more optimistic vision for its overall HIV business. Riding on the growth of long-acting antiretroviral therapy Cabenuva, GSK is laying out a more optimistic vision for its overall HIV business.

105

105

The FDA Law Blog

JANUARY 18, 2023

The memorandum outlines CMS’s priorities and timeline for the Initial Price Applicability Year 2026. The topics focus on issues relevant in the first three years of the Negotiation Program—2026 to 2028. Finally, the memorandum has a handy timeline of the key dates associated with the Initial Price Applicability Year 2026.

Dosage 59

Dosage 59

pharmaphorum

MAY 3, 2024

AI-powered home healthcare model from Cera could save NHS and UK £1bn in 2026 if adopted nationwide, says new study

108

108

Fierce Pharma

MARCH 18, 2024

As bluebird bio works to make the most of three gene therapy launches, cash-flow concerns have been looming over the drugmaker. | The funding should extend bluebird bio's cash runway through the first quarter of 2026 as it advances three gene therapy launches.

114

114

Outsourcing Pharma

SEPTEMBER 17, 2024

One year after a rejection by the US Food and Drug Administration (FDA), the UK firm F2G has raised $100 million to push its candidate olorofim to the market for the treatment of rare fungal infections in 2026.

FDA 107

FDA 107

STAT

AUGUST 13, 2024

In a press release, the company said that the cuts would help it extend its cash reserves from the second half of 2026 into 2028. The Bay Area biotech brought in $32 million during the quarter but also reported a net loss of $1.6 Continue to STAT+ to read the full story…

143

143

STAT

FEBRUARY 1, 2024

  The negotiated prices won’t take effect until 2026.  The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends.    Continue to STAT+ to read the full story…

Pharmaceutical Companies 129

Pharmaceutical Companies Pharmaceutical Companies 129

STAT

APRIL 16, 2024

It would carve grocers, restaurants, and food warehouses out of a major portion of the FDA’s rules, which are meant to help regulators quickly track down the cause of a foodborne outbreak, and it would delay enforcement of the entire food safety program, slated to begin in 2026, by several years.

FDA 141

FDA 141

PharmaVoice

OCTOBER 23, 2024

As Sanofi prepares to halt production on its dengue vaccine in 2026, locally acquired infections in the U.S. are raising the alarm.

Vaccines 98

Vaccines 98

Fierce Pharma

JANUARY 4, 2024

The Seattle-based CDMO has unveiled its plan to construct a four-story complex, which will cover 20,000 square meters (215,000 square feet) and is expected to become operational in 2026.

115

115

STAT

OCTOBER 9, 2024

The Congressional Budget Office estimates that 29 million beneficiaries would qualify for weight loss drugs in 2026.    Drugs for those conditions already exist, and they’re often generic. But a lot of people are switching to GLP-1s.   Continue to STAT+ to read the full story…

133

133

Pharmaceutical Commerce

AUGUST 16, 2024

By 2026, the first 10 drugs for individuals with Part D coverage—whose medications are mainly used to treat cancer, diabetes, and heart disease—will see discounts off of list prices ranging from 38-79%.

98

98

Fierce Pharma

SEPTEMBER 5, 2023

The case was filed Friday in New Jersey federal court, three days after the CMS revealed that Novartis’ heart failure treatment Entresto was among 10 drugs subject to price negotiations in 2026.

122

122

Fierce Pharma

MARCH 7, 2024

By Eisai’s 2026 fiscal year—which ends in March 2027—the company figures its Alzheimer's disease drug Leqembi can bring home 290 billion Japanese yen (nearly $2 billion) in global revenues. Come fiscal year 2032, those sales could potentially swell to a whopping 1.3 trillion yen ($8.8 billion).

110

110

STAT

SEPTEMBER 20, 2024

The new guidance will affect nearly 6,000 universities and other institutions with projects funded by HHS, which have until 2026 to comply.

134

134

Fierce Pharma

SEPTEMBER 3, 2024

28, 2026. Reddy’s formulations production plant, China’s National Medical Products Administration has suspended the import, sale and use of the Indian drugmaker’s atomoxetine hydrochloride capsules for ADHD. In addition, Dr. Reddy’s is prohibited from taking part in China’s drug procurement scheme through Feb.

105

105

Fierce Pharma

OCTOBER 9, 2023

billion) for exclusive rights to distribute the shingles shot in China from 2024 through 2026. GSK has forged a partnership with vaccine powerhouse Chongqing | GSK has forged a partnership with vaccine powerhouse Chongqing Zhifei Biological Products to distribute Shingrix in China. Zhifei will pay £2.5 billion ($3.05

Vaccines 116

Vaccines 116

Fierce Healthcare

MAY 7, 2024

New legislation extends the pandemic provisions for two more years, through 2026. | Pandemic-era Medicare telehealth flexibilities which removed restrictions on how a Medicare beneficiary could access telehealth are set to expire at the end of 2024. The offsets for the bill include pharmacy benefit manager reforms.

105

105

STAT

JUNE 18, 2024

Freespira CEO Joe Perekupka told STAT the company believes it will break even by the end of 2025 and will become cash flow positive in 2026. Perekupka said Freespira hopes to enroll 2,500 people in its treatment this year — twice last year’s sales — and to double its patients again in 2025 and 2026.

Insurance 104

Insurance 104

STAT

SEPTEMBER 4, 2024

The sites are expected to employ another 90 people and open by 2026.  The pharmaceutical giant will spend more than $200 million to construct the new facility in Carlsbad, Calif., and expand its site in Indianapolis, representatives told STAT exclusively.

119

119

Drug Store News

FEBRUARY 24, 2023

Target plans to spend $100 million to expand its package-sorting network to more than 15 facilities by the end of 2026.

Packaging 98

Packaging 98

Fierce Pharma

SEPTEMBER 12, 2023

28, 2026. The deal clears “all pending claims” and tees up a potential Dasynoc launch on Sept. 1, 2024, or potentially earlier under certain circumstances. The Sprycel patents in question aren’t due to expire until Sept.

FDA 116

FDA 116

Fierce Pharma

OCTOBER 7, 2024

GSK’s ViiV healthcare unit is countering rival HIV drugmaker Gilead’s recent global access moves with its own pledge to make at least 2 million doses of its long-acting pre-exposure prophylaxis (Pr | The long-acting HIV PrEP maker pledged to make at least 2 million more doses available for low-and middle-income countries in 2025 and 2026.

98

98

Outsourcing Pharma

OCTOBER 3, 2024

The proceeds of the financing will support the development of LoQus23âs lead candidate, a small molecule inhibitor that is expected to enter the clinic in 2026.

90

90

STAT

JUNE 24, 2024

But that deal, though eventually closed, was scuttled by regulatory issues in both the U.S. and Europe, and European regulators forced Illumina to spin Grail back out. Grail now says it expects to file for full approval in the U.S. In the meantime, the company is running an annual loss of about $500 million a year.

129

129

Drug Store News

JULY 31, 2023

Sandoz will invest roughly $90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia, by 2026.

97

97

STAT

SEPTEMBER 8, 2023

The negotiation, informed by confidential data from manufacturers and analysis by the Centers for Medicare and Medicaid Services, will result in a maximum fair price for each drug, which will be announced Sept. 1, 2024, and will take effect Jan. The Congressional Budget Office has estimated that the negotiations could save Medicare about $3.7

128

128